Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Long-Term Investments (2018 - 2025)

Historic Long-Term Investments for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $66.2 million.

  • Takeda Pharmaceutical's Long-Term Investments fell 2070.28% to $66.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $66.2 million, marking a year-over-year decrease of 2070.28%. This contributed to the annual value of $70.9 million for FY2025, which is 9699.9% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Long-Term Investments of $66.2 million as of Q4 2025, which was down 2070.28% from $60.5 million recorded in Q3 2025.
  • Takeda Pharmaceutical's Long-Term Investments' 5-year high stood at $2.3 billion during Q1 2024, with a 5-year trough of $60.5 million in Q3 2025.
  • For the 5-year period, Takeda Pharmaceutical's Long-Term Investments averaged around $848.0 million, with its median value being $707.7 million (2022).
  • Per our database at Business Quant, Takeda Pharmaceutical's Long-Term Investments skyrocketed by 1651.11% in 2021 and then crashed by 9692.09% in 2025.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Long-Term Investments stood at $919.4 million in 2021, then dropped by 27.3% to $668.4 million in 2022, then grew by 4.57% to $698.9 million in 2023, then crashed by 88.06% to $83.5 million in 2024, then dropped by 20.7% to $66.2 million in 2025.
  • Its last three reported values are $66.2 million in Q4 2025, $60.5 million for Q3 2025, and $68.7 million during Q2 2025.